Sowell Financial Services 13F: New $3.1M Stake in MBX
Key Points
- Sowell Financial Services opened a new stake in MBX Biosciences, Inc. with 53,077 shares valued at about $3.11 million.
- MBX Biosciences shares recently traded around $53.93, sitting 25.8% below their 52-week high and well above their low.
- Wall Street maintains a strong buy consensus with ten analysts covering the clinical-stage biotech firm.
Since the filing, $MBX is up 0.8% to date (from the $53.50 close on Oct 20, 2026).
Get MBX Biosciences text alerts
We text you when insiders, Congress, analysts or big funds move on $MBX.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated MBX Biosciences, Inc. alert may contain errors. Disclosures
Sowell Financial Services disclosed a new stake in MBX Biosciences, Inc. (NASDAQ:MBX) by acquiring 53,077 shares valued at approximately $3.11 million. The firm revealed the investment in a Form 13F filing filed with the Securities and Exchange Commission on October 20, 2026.
MBX
MBX Biosciences, Inc.
Sowell Financial Services vs. the S&P 500
Hypothetical returns from Sowell Financial Services's disclosed trades, not real profit or advice. How we model this.
What Changed in Sowell Financial Services's MBX Biosciences Position
Sowell Financial Services initiated a brand-new position in the clinical-stage biotechnology company during the period. The fund purchased 53,077 shares, bringing its total reported holding value to $3,111,374.
Other Institutional Activity in MBX Biosciences
Other major institutional investors adjusted their holdings in the biotech firm around the same reporting period. Frazier Life Sciences Management, L.P. held 6,652,013 shares worth about $358.74 million with no change in share count. NEA Management Company, LLC kept its holdings steady at 3,614,486 shares valued at roughly $194.93 million. Orbimed Advisors LLC. trimmed its stake by 209,180 shares, ending with 3,428,736 shares worth about $184.91 million. Paradigm Biocapital Advisors LP grew its holdings by 1,254,008 shares, ending with 2,508,015 shares worth roughly $135.26 million. NVP Associates, LLC held 2,136,335 shares valued at about $115.21 million without changing its share count.
MBX Biosciences, Inc. Stock Up 0.8%
MBX Biosciences shares recently traded around $53.93 as of October 22, 2026. The stock sits 10.0% below its 50-day moving average of $59.93 and 20.0% above its 200-day moving average of $44.94. The recent price is 25.8% below the 52-week high of $72.64 and 269.1% above the 52-week low of $14.61. The company has a market capitalisation of roughly $2.60 billion and a negative trailing earnings per share of $2.37, meaning it currently lacks a traditional price-to-earnings ratio.
Recent Earnings
MBX Biosciences reported a trailing twelve-month net profit margin of 0.0% and a return on equity of -33.2%. The firm maintains a current ratio of 18.08 and a quick ratio of 17.82, alongside a debt-to-equity ratio of 0.82. The next corporate earnings release is scheduled for November 5, 2026.
Insider Buying and Selling at MBX Biosciences, Inc.
Company insiders executed several transactions prior to the filing. Chief Executive Officer P Kent Hawryluk sold 607 shares on May 6, 2026, at an average price of $29.54 for a total value of $17,931. Officer Salomon M.D. Azoulay sold 231 shares on May 6, 2026, at $29.54 per share for $6,824, followed by the sale of 70,003 shares on May 8, 2026, valued at $2,685,515. Azoulay later sold 370 shares on August 4, 2026, at $65.77 per share for a total of $24,335.
Analysts Set New Price Targets
Wall Street firms updated their views on the stock over recent months. On July 29, 2026, Mizuho maintained an Outperform rating with a $91.00 price target, moving up from $57.00. Truist Securities maintained a Buy rating on August 10, 2026, raising its target to $88.00 from $70.00. Guggenheim maintained a Buy rating on October 2, 2026, lifting its target to $150.00 from $88.00. Stifel maintained a Buy rating on October 12, 2026, moving its target to $84.00 from $70.00. Ten analysts currently cover the stock, giving it a consensus recommendation of strong buy and a mean price target of $95.70.
About MBX Biosciences
MBX Biosciences, Inc. is a Carmel, Indiana-based clinical-stage biopharmaceutical company with 63 employees. The business focuses on discovering and developing precision peptide therapies to treat endocrine and metabolic disorders. Its lead product candidate is Canvuparatide, a parathyroid hormone peptide prodrug currently in Phase 3 clinical trials for chronic hypoparathyroidism.
Bottom Line
Sowell Financial Services added a brand-new stake in the clinical-stage biotech firm during the period. Investors will look toward the upcoming earnings update on November 5, 2026, for further operational details on its clinical pipeline.
Related Filing Alerts
Source: Sowell Financial Services's 13F filing on $MBX (Oct 20, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts